Figure Legends
Figure 1: Effect of mepolizumab on blood and sinonasal tissue
eosinophil levels. Blood samples and tissue biopsies were collected
during baseline, 4, 8, 16, 24 week visits, prior to Mepolizumab
administration. Blood eosinophil levels and tissue eosinophil counts per
0.1mm2 were evaluated and represented as mean
values±standard deviation of 20 eCRS participants.
Figure 2: Effect of mepolizumab on sinonasal tissue
eosinophil levels. Representative microscopic images of medium power
view of haematoxylin and eosin (H&E) (A, B) of a single patient at
baseline (A) and end of treatment (B).
Figure 3: Cytokine response in sinonasal tissue following
treatment with mepolizumab. Type-2 (A-D), type-1 (E, F) and regulatory
(G) cytokine levels in homogenised sinonasal tissue biopsies were
measured by immunoassay at baseline and end of treatment of 20 patients
with eosinophilic chronic rhinosinusitis patients treated with
mepolizumab. Data was statistically analysed by paired T tests. Data is
presented as mean values +/- SD and analysed by paired T test. ns = P
> 0.05; * = P ≤ 0.05; ** = P ≤ 0.01; *** = P ≤ 0.001.